Cadila Healthcare receives DCGI grant for phase 3 trials of ZyCoV-D

By Nikita Chaurasia  | Date: 2021-01-04

Cadila Healthcare receives DCGI grant for phase 3 trials of ZyCoV-D

Indian pharmaceutical company Cadila Healthcare Limited, commonly known as Zydus Cadila, has made it to the headlines after receiving the approval of the DCGI (Drugs Controller General of India) for the Phase 3 clinical trials of its Coronavirus vaccine ZyCoV-D.

For the uninitiated, ZyCoV-D is a plasmid DNA, which translates into viral proteins when introduced into the host cells in order to trigger a robust immune response, facilitated by the humoral and cellular arms of the human immune system.

The Phase 3 trial round will include around 30000 volunteers. Sources confirmed that the company plans on initiating the launch as well as administration of the vaccine in the first quarter of the next financial year if the trial results are in its favor.

Reportedly, ZyCoV-D was proven to be well-tolerated, safe and immunogenic in its phase-1 and phase-2 clinical trials. It is also worth mentioning that the phase-2 trial round was conducted on around 1000 volunteers and included a randomized, multi-centric, dose-escalation double-blind placebo-controlled study.

The phase-2 trials were reviewed by an independent DSMB (Data Safety Monitoring Board) and the reports of the safety outcomes were submitted to the CDSCO (Central Drugs Standard Control Organization). Zydus Cadila then called for the DCGI approval after the phase-2 trials concluded positive outcomes.

Chairman of Zydus Group, Pankaj Patel was reported saying that the DCGI approval marks a significant milestone for the company’s vaccine development program. The phase-3 trials will ascertain the efficacy of ZyCoV-D in the treatment of Covid-19, he added.

The introduction of ZyCoV-D, developed in the company's Ahmedabad-based Vaccine Technology Centre, has paved the way for the establishment of a DNA vaccine platform in India, sources claimed. This platform has proven to improve vaccine stability and hence requires lower cold chain storage.

Moreover, Zydus Cadila has reportedly employed around 300 scientists to conduct comprehensive research on the vaccine, with around 1,400 researchers working on pharmaceutical technologies, biologicals and chemical entities (NCEs).

Source credits –

https://www.business-standard.com/article/current-affairs/zydus-gets-dcgi-nod-for-conducting-phase-3-clinical-trials-of-zycov-d-121010300466_1.html

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More >>

More News By Nikita Chaurasia

Swiftly achieves Unicorn status with $100M Series C led by BRV Capital

Swiftly achieves Unicorn status with $100M Series C led by BRV Capital

By Nikita Chaurasia

Swiftly Systems has reportedly achieved unicorn status, securing in funding through a Series C round. The prominent BRV Capital Management led this funding initiative. According to the earlier reports, Swiftly was adopted by hundreds of consumer b...

Rainforest nations unify to demand cash for climate & biodiversity preservation

Rainforest nations unify to demand cash for climate & biodiversity preservation

By Nikita Chaurasia

As per the reports, twelve nations with rainforests united to establish a collective initiative aiming to address climate change and safeguard biodiversity at summit held in Brazil. The declaration, titled "United for Our Forests," emerged ...

AI Chatbot, Llama 2, unveiled by Meta for commercial use via Microsoft

AI Chatbot, Llama 2, unveiled by Meta for commercial use via Microsoft

By Nikita Chaurasia

Meta Platforms has recently introduced Llama 2, an artificial intelligence large language model, for commercial use in collaboration with major cloud providers like Microsoft. Instead of charging for access or usage, Meta aims to share the model with...

Moderna signs agreement to explore mRNA medicines in China

Moderna signs agreement to explore mRNA medicines in China

By Nikita Chaurasia

Moderna Inc, a leading vaccine manufacturer, reportedly announced on Wednesday that it has entered into a memorandum of understanding (MoU) and a land collaboration agreement aimed at exploring opportunities for researching, developing, and producing...

Nike and Epic Games collaborate to launch Airphoria NFT in Fortnite

Nike and Epic Games collaborate to launch Airphoria NFT in Fortnite

By Nikita Chaurasia

The American footwear design & manufacturing company, Nike and Epic Games, the creators of the popular online game Fortnite, have joined forces in an exciting new collaboration. The partnership aims to bring about a groundbreaking change in the d...